Information Provided By: 
Fly News Breaks for December 9, 2019
BLUE
Dec 9, 2019 | 07:44 EDT
Canaccord analyst John Newman lowered his price target on Bluebird Bio to $118 from $171 to reflect competition on its best-in-class status bb2121. The ASH conference saw competitors present strong data and along with the unclear reimbursement environment for CAR-T products, the unsure timing for bb2121, and model adjustments, he lowered his target. Newman reiterated his Buy rating on Bluebird Bio shares.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
